New data from iRhythm Technologies show that extending ECG monitoring to 14 days captures significantly more arrhythmia recurrences in post-ablation and pregnant patients than the standard 24-48 hours ...

Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 ...

Cardiac monitoring belongs foundation of service line strategy to improve cardiovascular care access, reduce delays, and ...

iRhythm Technologies IRTC recently announced initial research findings on the post-market, real-world performance of the Zio monitor, IRTC’s next-generation Zio long-term continuous monitoring (LTCM) ...

SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC) (NASDAQ:IRTC) today announced initial research findings on post-market, real-world performance of Zio ® monitor, its ...

New research presented at the Heart Rhythm Society’s 2026 meeting shows that 14-day continuous monitoring with iRhythm’s Zio patch detects significantly more atrial fibrillation recurrences than the ...

iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...

iRhythm Technologies today unveiled initial findings on the post-market and real-world performance of its Zio monitor, building on the devices previous generation of the long-term continuous ...

Heart disease, particularly conditions like atrial fibrillation (AFib), is a leading cause of death worldwide, and traditional cardiac monitoring methods often present challenges in patient comfort ...